Out of stock
$70.00 — or subscribe and save 20%
99% Pure | USA Made | Multi DoseCartalax Peptide is a short-chain peptide studied for its regenerative potential in connective tissue, particularly cartilage. Originating from Russian peptide research programs, Cartalax has shown promise in models exploring cartilage health, joint recovery, and overall musculoskeletal function. This research peptide is a fragment of naturally occurring cytomodulins and has been studied for its influence on gene expression in cartilage cells, including chondrocytes. Its application in peptide science centers on its ability to signal the regulation of protein synthesis pathways, modulate inflammation, and support healthy tissue maintenance — making it a molecule of high interest in the field of regenerative peptide research. Real Peptides provides Cartalax in high-purity, USA-manufactured vials, independently third-party tested and designed exclusively for research professionals.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
Cartalax is a synthetic peptide fragment derived from naturally occurring cytomax proteins found in connective tissue, specifically those involved in cartilage structure and signaling. This short-chain peptide was originally developed and studied in Russian peptide bioregulation programs and has since gained attention in Western research for its ability to regulate gene expression in chondrocytes (cartilage cells). Cartalax is part of a broader class of peptides known as bioregulatory peptides, which are designed to influence protein synthesis and cellular behavior at a targeted tissue level.
In the laboratory, Cartalax has been explored for its potential to influence regenerative mechanisms in connective tissue, reduce inflammatory signals within the extracellular matrix, and provide peptide-based signaling that supports the structural integrity of cartilage. These studies often involve models of joint degradation, aging cartilage, and degenerative musculoskeletal conditions. Because Cartalax is a tissue-specific peptide, its action is believed to be more targeted than general regenerative peptides, making it a valuable molecule in peptide-based research on osteoarthritic changes, cartilage regeneration, and immune modulation in musculoskeletal systems.
Its small molecular structure allows it to be absorbed and distributed rapidly in tissue models, where it may support reparative processes at the genetic level without triggering broad systemic responses. This makes Cartalax particularly interesting in controlled studies where localized outcomes are preferred.
Cartalax is a standout in peptide research due to its specificity, safety profile in controlled models, and growing body of data surrounding its effects on joint and cartilage function. Unlike more generalized regenerative peptides such as BPC-157 or TB-500, Cartalax operates with tissue specificity, targeting only those cells involved in cartilage repair and signaling.
For researchers exploring:
Cartalax presents a high-value, precision molecule for in-depth experimentation. Its ability to potentially regulate cytokines, repair matrix protein expression, and rebalance cell signaling in connective tissue models provides a framework for applications in both preventative and reparative biological study.
In combination with other tissue-support peptides like TB-500, Epithalon, or Thymalin, Cartalax can be a cornerstone compound in comprehensive peptide research stacks.
Researchers choose Cartalax for its:
What distinguishes Cartalax from other regenerative peptides is its focused mechanism of action and history of clinical research within Russian bioregulation protocols. While many peptides support broad healing or systemic hormone release, Cartalax has been studied primarily for its localized effect on gene regulation within cartilage tissue.
Key differentiators include:
1. Cartilage-Specific Bioregulation
Cartalax is not a growth hormone secretagogue or a systemic modulator. Its pathway influences the expression of genes involved in cartilage integrity, including proteoglycans and type II collagen—making it extremely relevant for research in osteoarthritis and joint degradation.
2. Non-Hormonal, Low-Side Effect Profile
Because Cartalax does not stimulate hormone pathways or GH/IGF-1 axes, it’s ideal for studies requiring minimal systemic interference. Its non-hormonal nature allows it to be studied in conjunction with other peptides or agents without disrupting hormonal baselines.
3. Legacy of Clinical Application
Cartalax was one of several peptides developed by the St. Petersburg Institute of Bioregulation and Gerontology, with over 30 years of clinical and preclinical exploration. This legacy provides researchers with a roadmap of peer-reviewed data and case modeling.
4. Excellent Compatibility with Recovery and Performance Peptides
Because it complements peptides like BPC-157 and GHK-Cu, Cartalax fits well into joint recovery and anti-aging stacks designed for layered tissue regeneration. Researchers aiming to explore complex reparative models can confidently include Cartalax in combination trials.
5. Purity and Consistency at Real Peptides
At Real Peptides, Cartalax is available with 99%+ purity, produced under USA lab conditions with full third-party testing and documentation available. Each batch is consistent, research-grade, and made for investigators who require reliable, reproducible results.
Whether you’re exploring long-term tissue aging or immediate post-injury peptide signaling, Cartalax offers one of the most cartilage-specific, targeted molecules available in today’s peptide research landscape.
Don't hestitate to contact us
End of Content.
